Expert consensus on maintenance treatment for metastatic colorectal cancer in China

Springer Science and Business Media LLC - Tập 35 Số 1 - 2016
Rui Xu1, Lin Shen2, Jin Li3, Jian Xu4, Feng Bi5, Yi Ba6, Bai Li7, Yongqian Shu8, Tian Shu Liu9, Yu Hong Li10, Chun Mei Bai11, Xianglin Yuan12, Jun Zhang13, Gong Chen14, Ai-Ping Zhou15, Ying Yuan16, Xi Jing Wang17, Xiao Ping Qian18, Yuxin Deng19
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, 510060, Guangdong, P. R. China
2Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, 100142, P. R. China
3Department of Oncology, Tongji University Tianyou Hospital, Shanghai, 200331, P. R. China
4Department of Medical Oncology, The 307th Hospital of Chinese People’s Liberation Army, Beijing, 100071, P. R. China
5Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, 610041, Sichuan, P. R. China
6Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, P. R. China
7Department of Medical Oncology, The 301th Hospital of Chinese People’s Liberation Army, Beijing, 100853, P. R. China
8Department of Medical Oncology, Jiangsu Provincial Hospital, Nanjing, 210029, Jiangsu, P. R. China
9Department of Medical Oncology, Fudan University Zhongshan Hospital, Shanghai, 200032, P. R. China
10Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong, P. R. China
11Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, 100032, P. R. China
12Department of Medical Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, P. R. China
13Department of Oncology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200035, P. R. China
14Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China
15Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, 100021, P. R. China
16Department of Medical Oncology, The Second Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, P. R. China
17Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710004, Shanxi, P. R. China
18Department of Medical Oncology, Nanjing Drum Tower Hospital, Nanjing, 210008, Jiangsu, P. R. China
19Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, P. R. China

Tóm tắt

Từ khóa


Tài liệu tham khảo

Chen WQ, Zheng RS, Zhang SW, Zeng HM, Zou XN. The incidences and mortalities of major cancers in China, 2010. Chin J Cancer. 2014;33:402–5.

Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III ‘Stop and Go’ study results–a Turkish Oncology Group Trial. Oncology. 2013;85:328–35.

Waddell T, Gollins S, Soe W, Valle J, Allen J, Bentley D, et al. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Cancer Chemother Pharmacol. 2011;67:1111–7.

Li Y, Li J, Lu M, Wang XC, Shen L. Capecitabine maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer. Chin J Cancer Res. 2010;22:181–5.

Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385:1843–52.

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol. 2006;24:394–400.

Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol. 2009;27:5727–33.

Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer. 2011;30:682–9.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706–12.

Bai L, Zhang DS, Wu WJ, Ren C, Wang DS, Wang F, et al. Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Med Oncol. 2015;32:469.

Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol. 2014;20:3858–74.

Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, et al. Right- and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 2015;34:24.

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1–9.

Arnold D, Graeven U, Lerchenmuller CA, Killing B, Depenbusch R, Steffens CC, et al. Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): a phase III non-inferiority trial (AIO KRK 0207). ASCO Annual Meeting Proceedings; 2014.

Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, et al. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010;136:503–10.

Xu R, Li Y, Luo H. Continuing single-agent capecitabin as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2015;33:1.

Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17:15–25.

Alfonso PG, Benavides M, Ruiz AS, Guillen-Ponce C, Safont M, Alcaide J, et al. Phase II study of first-line mfolfox plus cetuximab (C) for 8 cycles followed by mfolfox plus C or single agent(S/A) C as maintenance therapy in patients (P) with metastatic colorectal cancer (mCRC): the MACRO-2 trial (Spanish Cooperative Group for the treatment of digestive tumors [TTD]). Ann Oncol. 2014;25:iv168.

Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.

Shi H, Jiang J, Ji J, Shi M, Cai Q, Chen X, et al. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer. Cancer Lett. 2014;349:128–35.

Hagman H, Frödin J, Berglund A, Sundberg J, Vestermark L, Albertsson M, et al. A randomized study of kras-stratified maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the NORDIC ACT2 trial. Ann Oncol. 2014;25:iv175.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 35 Số 1

Thông tin tác giả